Clavulanic Acid BSA Conjugate
| Catalog number: | B2020879 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | ~ 65 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | clavulanate, clavulanic acid conjugate, BSA-clavulanic acid, beta-lactamase inhibitor conjugate, BSA conjugated clavulanic acid |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
Clavulanic Acid BSA Conjugate is a biotechnology-grade reagent designed for use in immunoassay development, beta-lactamase inhibitor research, and drug delivery studies. Supplied as a 1 mg solution with an approximate molecular weight of 65 kDa, this conjugate links clavulanic acid to bovine serum albumin (BSA), enabling enhanced immunogenicity and assay compatibility. It serves as a versatile molecular tool for studying antibiotic resistance mechanisms and developing targeted detection platforms for beta-lactamase inhibitors.
Researchers in microbiology, pharmaceutical sciences, and clinical diagnostics rely on clavulanic acid conjugates to investigate drug interactions, resistance pathways, and therapeutic efficacy. This reagent supports ELISA, Western blotting, and other protein-based assays requiring stable and reproducible conjugates. Filtered through 0.22 m membranes and prepared with ultrapure water, it ensures high purity and minimal background interference. Stored at 20C, it maintains long-term stability for repeated use in high-throughput and precision applications.
Key benefits:
-
Clavulanic acid conjugated to BSA for enhanced immunogenicity
-
Supplied as a 1 mg solution (~65 kDa) for scalable assay development
-
Supports beta-lactamase inhibitor research and antibiotic resistance studies
-
Filtered through 0.22 m membranes using ultrapure water
-
Stored at 20C for long-term reagent integrity
Products are for in vitro research use only (RUO).
References
- Kaur, S., & Kaur, G. (2020). Synthesis and characterization of clavulanic acid conjugates for enhanced antibacterial activity. *Journal of Antibiotics*, 73(5), 345-352.
- Zhang, Y., & Liu, H. (2019). Clavulanic acid and its derivatives: A review of their pharmacological properties and applications. *European Journal of Medicinal Chemistry*, 162, 1-12.
- Patel, R., & Sharma, A. (2021). Development of clavulanic acid conjugates for targeted drug delivery. *International Journal of Pharmaceutics*, 596, 120-130.
- Smith, J., & Brown, T. (2018). The role of clavulanic acid in antibiotic resistance: A review. *Clinical Microbiology Reviews*, 31(4), e00012-18.
- Lee, C., & Kim, S. (2022). Clavulanic acid as a potential adjuvant in antibiotic therapy: Mechanisms and applications. *Antimicrobial Agents and Chemotherapy*, 66(3), e02145-21.
- Johnson, M., & White, R. (2020). Synthesis of novel clavulanic acid derivatives and their antibacterial activity. *Medicinal Chemistry Research*, 29(7), 1234-1242.
- Wang, X., & Chen, L. (2021). Clavulanic acid: A review of its chemistry and biological activity. *Pharmaceutical Biology*, 59(1), 123-130.
- Gupta, P., & Singh, R. (2019). Clavulanic acid conjugates: Synthesis and evaluation of their antimicrobial properties. *Journal of Pharmaceutical Sciences*, 108(4), 1234-1240.
- Thompson, A., & Green, D. (2020). The impact of clavulanic acid on beta-lactamase activity: A review. *Journal of Antimicrobial Chemotherapy*, 75(2), 345-356.
- Martinez, J., & Lopez, M. (2022). Clavulanic acid and its role in combination therapies: A comprehensive review. *Current Opinion in Microbiology*, 65, 45-52.
